Johnson & Johnson (JNJ) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 28, 2025. Johnson & Johnson operates as a holding company with approximately 138,200 employees worldwide, organized into two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company conducts business in virtually all countries, with a strategic focus on human health and well-being. In October 2025, the company announced its intention to separate its Orthopaedics business, targeting completion within 18 to 24 months.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Sales | $94.2 billion | $88.8 billion | +6.0% |
| Net Earnings | $26.8 billion | $14.1 billion | +90.3% |
| Earnings Per Share (Diluted) | $11.03 | $5.79 | +90.5% |
| Operating Cash Flow | $24.5 billion | $24.3 billion | +0.8% |
| Total Debt | $47.9 billion | $36.6 billion | +30.9% |
| Cash & Cash Equivalents | $19.7 billion | $24.1 billion | -18.3% |
| Effective Tax Rate | 17.7% | 15.7% | +2.0% |
Segment Performance: Innovative Medicine sales grew 6.0% to $60.4 billion. MedTech sales grew 6.1% to $33.8 billion. The company invested $14.7 billion in research and development in 2025.
Material Changes vs. Prior Period
- Significant Earnings Increase: Net earnings nearly doubled compared to 2024, primarily driven by a $7.0 billion reversal of previously accrued talc litigation reserves following the dismissal of a bankruptcy case in Texas. In contrast, 2024 included a $5.1 billion charge for talc matters.
- Revenue Growth Drivers: Worldwide sales growth of 6.0% was driven by volume (+8.4%) and currency (+0.7%), partially offset by price (-3.1%). Acquisitions contributed a net positive 1.1% to sales growth.
- Product Mix Shifts:
- Growth: Oncology sales rose 22.1% (driven by DARZALEX, CARVYKTI, ERLEADA). Neuroscience sales increased 10.1% (driven by SPRAVATO and the acquisition of CAPLYTA). Cardiovascular MedTech sales surged 15.8% (driven by Shockwave and Abiomed).
- Declines: Immunology sales fell 11.8% due to a 41.3% decline in STELARA sales from biosimilar competition. Infectious Diseases sales dropped 4.6% due to lower COVID-19 vaccine revenue.
- Debt Position: Total debt increased by $11.3 billion, largely due to $9.2 billion in senior unsecured notes issued in Q1 2025 to fund the Intra-Cellular Therapies acquisition and general corporate purposes.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Separation: The company plans to separate its Orthopaedics business (DePuy Synthes) via multiple potential paths, with completion targeted for 18-24 months post-announcement. This separation is expected to incur significant costs.
- Acquisitions: The company completed the acquisition of Intra-Cellular Therapies (CAPLYTA) for $14.5 billion and Halda Therapeutics for $3.05 billion in 2025.
- Regulatory & Pricing Risks: The Inflation Reduction Act (IRA) impacts pricing for selected drugs (e.g., XARELTO, STELARA, ERLEADA) starting in 2026. The company is litigating the constitutionality of the IRA's drug price negotiation program.
- Legal Contingencies:
- Talc: Following the Texas bankruptcy dismissal, the company returned to the tort system. The current reserve is approximately $3.4 billion. Ovarian cancer trials are scheduled for 2026.
- Opioids: Approximately 80% of the $5.0 billion state settlement has been paid. Litigation continues with remaining government and private plaintiffs.
- Intellectual Property: Significant patent challenges exist for key products like STELARA, TREMFYA, and XARELTO, with biosimilar and generic launches expected to impact future revenues.
- Unusual Items: The $7.0 billion talc reserve reversal is a non-recurring item that significantly inflated 2025 earnings. Additionally, the company recorded a $0.8 billion judgment related to the Auris shareholder litigation in Q4 2025.
Investor Verification Checklist
- Talc Litigation Reserve: Verify the sustainability of the $3.4 billion reserve and the potential for future accruals as the company returns to the tort system for talc claims.
- STELARA Biosimilar Impact: Assess the long-term revenue trajectory of the Immunology segment given the 41% decline in STELARA sales and the expected global launch of biosimilars.
- Orthopaedics Separation: Monitor the timeline and financial impact of the planned separation of the Orthopaedics business, including restructuring costs and potential tax implications.
- IRA Pricing Implementation: Evaluate the financial impact of the Inflation Reduction Act price negotiations on key products (XARELTO, STELARA, ERLEADA) beginning in 2026.
- Debt Servicing: Review the company's ability to service the increased debt load ($47.9 billion) while maintaining its dividend (increased to $5.14/share in 2025) and funding R&D.